DAB2IP

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

Retrieved on: 
Monday, October 23, 2023
AACR, RAS, Breast, MAPK, Prevalence, Conference, NF1, KRAS, University of Louisville School of Medicine, RAL, DAB2IP, Cancer, Partnership, Breast cancer, University, Downregulation and upregulation, Therapy, American Association for Cancer Research, Pharmaceutical industry

CARLSBAD, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces a poster presentation on the Company’s Pan-RAS platform at the American Association for Cancer Research (AACR) Special Conference in Breast Cancer Research, held October 19th to 22nd at the Westin San Diego Bayview.

Key Points: 
  • “The RAS pathway continues to be an area of immense interest within the scientific community and biopharmaceutical industry.
  • Due to the prevalence and severity of RAS-driven tumors, there is a high unmet need to discover and develop more broadly acting RAS-targeted compounds.
  • These effects are particularly common in Luminal B breast cancer.
  • As a result, we have developed a series of novel direct Pan-RAS inhibitors that exhibit a distinct binding mechanism to other currently described RAS inhibitors.